FDA pregnancy risk categories and the CPS: Do they help or are they a hindrance?

Canadian Family Physician

Volumn 56, Issue 3, 2010, Pages 239-241

  Law, Ruth ^a   Bozzo, Pina ^a   Koren, Gideon ^a   Einarson, Adrienne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG SAFETY; DRUG USE; FEMALE; HEALTH PROGRAM; HUMAN; MATERNAL CARE; MEDICAL LITERATURE; PATIENT SAFETY; PREGNANCY; PRENATAL DRUG EXPOSURE; RISK ASSESSMENT; SHORT SURVEY;

ABNORMALITIES, DRUG-INDUCED; ADULT; CHRONIC DISEASE; FEMALE; HUMANS; MATERNAL EXPOSURE; PHARMACEUTICAL PREPARATIONS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; REGISTRIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77949785077     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (15)

1. Garriguet D. Medication use among pregnant women. Health Rep 2006;17(2):9-18.
2. Trussell J. The cost of unintended pregnancy in the United States. Contraception 2007;75(3):168-70. Epub 2007 Jan 18.
3. Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol 2002;100(3):465-73.
4. Boothby LA, Doering PL. FDA labeling system for drugs in pregnancy. Ann Pharmacother 2001;35(11):1485-9.
5. Doering PL, Boothby LA, Cheok M. Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks? Am J Obstet Gynecol 2002;187(5):333-9.
6. Public Affairs Committee of the Teratology Society. Teratology Public Affairs Committee position paper: pregnancy labeling for prescription drugs: ten years later. Birth Defect Res A Clin Mol Teratol 2007;79(9):627-30.
7. Feibus KB. FDA's proposed rule for pregnancy and lactation labeling: improving maternal child health through well-informed medicine use. J Med Toxicol 2008;4(4):284-8.
8. Einarson A, Park A, Koren G. How physicians perceive and utilize information from a teratogen information service: the Motherisk Program. BMC Med Educ 2004;4:6.
9. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14(12):823-7.
10. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356(26):2675-83.
11. Bellantuono C, Migliarese G, Gentile S. Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review. Hum Psychopharmacol 2007;22(3):121-8.
12. Prozac [product monograph]. In: Repchinsky C, editor-in-chief. Compendium of pharmaceuticals and specialties. Ottawa, ON: Canadian Pharmacists Association; 2009. Ottawa, ON; 2009. p. 1871.
13. Einarson A. Studying the safety of drugs in pregnancy: and the gold standard is... J Clinical Pharmacol and Pharmacoepidemiol 2008;1:3-8.
14. Einarson A. The way women perceive teratogenic risk: how it can influence decision making during pregnancy regarding drug use or abortion of a wanted pregnancy. In: Koren G, editor. Medication safety in pregnancy and breastfeeding. New York, NY: McGraw-Hill Companies; 2007. p. 309-12.
15. Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004;49(11):726-35.